| scholarly article | Q13442814 |
| P2093 | author name string | Feng Liu | |
| Lei Gao | |||
| Feng Xu | |||
| Shuo Zhang | |||
| Ting Wang | |||
| Jing Feng | |||
| Tian Yang | |||
| Mingwei Chen | |||
| Hui Ren | |||
| Hua Guo | |||
| Dong Shang | |||
| Puyu Shi | |||
| Tianjun Chen | |||
| Yiqian Liang | |||
| Johnson J Liu | |||
| Asmitananda Thakur | |||
| P2860 | cites work | Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation | Q38949674 |
| PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways | Q38951260 | ||
| Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance | Q38955141 | ||
| Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells | Q39053954 | ||
| Autophagy proteins regulate ERK phosphorylation | Q39062345 | ||
| Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway | Q39078533 | ||
| The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. | Q39317004 | ||
| MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors | Q39355055 | ||
| Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells. | Q39750232 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer | Q53410679 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor | Q27676347 | ||
| Autophagy in the Pathogenesis of Disease | Q27860558 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Autophagy: process and function | Q29547296 | ||
| Potential therapeutic applications of autophagy | Q29622862 | ||
| HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma | Q34017957 | ||
| Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability | Q34096767 | ||
| Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone | Q34420112 | ||
| Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. | Q35374899 | ||
| Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy | Q35556966 | ||
| Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells | Q35670413 | ||
| MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma | Q36021572 | ||
| A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells | Q36140634 | ||
| Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells | Q37203000 | ||
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition | Q37445131 | ||
| The E3 ubiquitin ligases β-TrCP and FBXW7 cooperatively mediates GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis | Q37583704 | ||
| Biomarkers with Predictive and Prognostic Function in Non–Small Cell Lung Cancer: Ready for Prime Time? | Q37777283 | ||
| Autophagy as a target for anticancer therapy | Q37876679 | ||
| Prognostic and predictive biomarkers in lung cancer. A review | Q38178187 | ||
| Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors | Q38406496 | ||
| Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis. | Q38536755 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| autophagy | Q288322 | ||
| P304 | page(s) | 67277-67287 | |
| P577 | publication date | 2016-08-27 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells | |
| P478 | volume | 7 |
| Q55322517 | Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer cells. |
| Q48651245 | ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma |
| Q90679554 | Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting |
| Q47122504 | Inhibition of HSP90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells |
| Q52363953 | Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53. |
| Q61455097 | Targeted therapies for advanced non-small cell lung cancer |
| Q47110143 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells |
| Q100415901 | The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells |
Search more.